Anaplastic thyroid cancer can spread rapidly in a matter of weeks. So it’s important to see your doctor right away. They will examine you and check for a lump or growth in your neck.

Anaplastic thyroid cancer is the rarest type of thyroid cancer and the most challenging to treat. Anaplastic thyroid cancer cases are only 1% of all thyroid cancer cases, and the cure rate is low. The ...

Two other types of thyroid cancer exist, although they are very rare, accounting for only 1-2% of diagnoses for medullary thyroid cancer and X% for anaplastic thyroid cancer. Today, I’d like to take ...

Anaplastic thyroid cancer (ATC) is a rare and aggressive form of cancer affecting the thyroid. Doctors usually treat it with surgery as well as chemotherapy and radiation. There are four types of ...

Anaplastic thyroid cancer has historically had very poor prognoses, with nearly 100% of cases being fatal. In stage IVB, the current standard of care has involved multimodal therapy, including ...

Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity ...

Overall survival rates for adults diagnosed with anaplastic thyroid carcinoma are similar between those with a history of cancer and those with no previous cancer diagnosis, according to findings ...

Among patients with unresectable anaplastic thyroid cancer treated with lenvatinib, average survival was prolonged. The study was published as a preprint and has not yet been peer reviewed.

Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. A trial of atezolizumab (Tecentriq ...

The thyroid plays an important role in producing hormones to regulate the body. Evidence suggests that in 2021, there are roughly 44,280 new cases of thyroid cancer, with 12,150 cases occurring in ...

Source Reference: Cabanillas ME, et al "Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: A nonrandomized clinical trial" JAMA Oncol 2024; DOI: 10.1001 ...